Not recruitingEUCTR 2010-018579-12
A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesADHD
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Bulgaria and 8 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 333
- Sponsor
- Shire Pharmaceutical Development Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Austria, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-018579-12
- Official title
Show the full official title
A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
Recruitment & locations
Not recruitingAustria · Bulgaria · France
7 more locations
- Germany
- Ireland
- Italy
- Netherlands
- Spain
- Sweden
- United Kingdom
Registry details
Historical country statuses
- Austria — Completed
- Bulgaria — Completed
- Germany — Completed
- Spain — Completed
- France — Completed
- United Kingdom — Completed
- Ireland — Completed
- Italy — Completed
- Netherlands — Prematurely Ended
- Sweden — Completed
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Shire Pharmaceutical Development Ltd, a pharmaceutical company.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, ...
